ST香雪：TAEST16001获临床试验批准

证券之星2025-11-13

证券之星消息，ST香雪(300147)11月12日在投资者关系平台上答复投资者关心的问题。

投资者提问：董秘您好，公司16001注射液新增的2个适应症，分别是晚期食道癌、晚期非小细胞肺癌，并且获得了临床试验许可。请问这2个新增的适应症是处于二期临床试验阶段吗？

ST香雪回复：您好，感谢对公司的关注。TAEST16001用于治疗晚期食管癌、晚期非小细胞肺癌，均已获得临床试验批准，暂未开展临床试验。后续研发进展会按照信息披露规则结合实际情况以公告的形式对外披露。谢谢！

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2583560548?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-13 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583560548","market":"fut","top_or_hot":-1,"title":"ST香雪：TAEST16001获临床试验批准","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/300147\">ST香雪</a>(300147)11月12日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：董秘您好，公司16001注射液新增的2个适应症，分别是晚期食道癌、晚期非小细胞肺癌，并且获得了临床试验许可。请问这2个新增的适应症是处于二期临床试验阶段吗？</p><p>ST香雪回复：您好，感谢对公司的关注。TAEST16001用于治疗晚期食管癌、晚期非小细胞肺癌，均已获得临床试验批准，暂未开展临床试验。后续研发进展会按照信息披露规则结合实际情况以公告的形式对外披露。谢谢！</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ST香雪：TAEST16001获临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nST香雪：TAEST16001获临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-13 20:48 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2025111300039789.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，ST香雪(300147)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司16001注射液新增的2个适应症，分别是晚期食道癌、晚期非小细胞肺癌，并且获得了临床试验许可。请问这2个新增的适应症是处于二期临床试验阶段吗？ST香雪回复：您好，感谢对公司的关注。TAEST16001用于治疗晚期食管癌、晚期非小细胞肺癌，均已获得临床试验批准，暂未开展临床试验。后续...</p>\n\n<a href=\"https://stock.stockstar.com/RB2025111300039789.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"https://stock.stockstar.com/RB2025111300039789.shtml","article_id":"2583560548","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583560548","pubTimestamp":1763038115,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，ST香雪(300147)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司16001注射液新增的2个适应症，分别是晚期食道癌、晚期非小细胞肺癌，并且获得了临床试验许可。请问这2个新增的适应症是处于二期临床试验阶段吗？ST香雪回复：您好，感谢对公司的关注。TAEST16001用于治疗晚期食管癌、晚期非小细胞肺癌，均已获得临床试验批准，暂未开展临床试验。后续研发进展会按照信息披露规则结合实际情况以公告的形式对外披露。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300147":"ST香雪","BK0060":"抗癌","BK0028":"国家队","BK0239":"医药制造","BK0070":"员工持股"},"translate_title":"ST Xiangxue: TAEST16001 was approved for clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300147":1.5},"content_text":"证券之星消息，ST香雪(300147)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司16001注射液新增的2个适应症，分别是晚期食道癌、晚期非小细胞肺癌，并且获得了临床试验许可。请问这2个新增的适应症是处于二期临床试验阶段吗？ST香雪回复：您好，感谢对公司的关注。TAEST16001用于治疗晚期食管癌、晚期非小细胞肺癌，均已获得临床试验批准，暂未开展临床试验。后续研发进展会按照信息披露规则结合实际情况以公告的形式对外披露。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583560548","isCrawlerRequest":true}